5xmx

From Proteopedia
Revision as of 11:06, 22 November 2023 by OCA (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Co-crystal structure of Inhibitor compound in complex with human PPARdelta LBDCo-crystal structure of Inhibitor compound in complex with human PPARdelta LBD

Structural highlights

5xmx is a 2 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2Å
Ligands:
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

PPARD_HUMAN Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand.[1] [2]

Publication Abstract from PubMed

Optimization of benzamide PPARdelta modulator 1 led to (E)-6-(2-((4-(furan-2-yl)-N-methylbenzamido)methyl)phenoxy)-4-methylhex-4-enoic acid (18), a potent selective PPARdelta modulator with significantly improved exposure in multiple species following oral administration.

Novel highly selective peroxisome proliferator-activated receptor delta (PPARdelta) modulators with pharmacokinetic properties suitable for once-daily oral dosing.,Lagu B, Kluge AF, Fredenburg RA, Tozzo E, Senaiar RS, Jaleel M, Panigrahi SK, Tiwari NK, Krishnamurthy NR, Takahashi T, Patane MA Bioorg Med Chem Lett. 2017 Dec 1;27(23):5230-5234. doi:, 10.1016/j.bmcl.2017.10.037. Epub 2017 Oct 27. PMID:29103972[3]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

See Also

References

  1. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol. 1992 Oct;6(10):1634-41. PMID:1333051 doi:http://dx.doi.org/10.1210/mend.6.10.1333051
  2. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res. 2005 Mar;46(3):526-34. Epub 2004 Dec 16. PMID:15604518 doi:http://dx.doi.org/10.1194/jlr.M400400-JLR200
  3. Lagu B, Kluge AF, Fredenburg RA, Tozzo E, Senaiar RS, Jaleel M, Panigrahi SK, Tiwari NK, Krishnamurthy NR, Takahashi T, Patane MA. Novel highly selective peroxisome proliferator-activated receptor delta (PPARdelta) modulators with pharmacokinetic properties suitable for once-daily oral dosing. Bioorg Med Chem Lett. 2017 Dec 1;27(23):5230-5234. doi:, 10.1016/j.bmcl.2017.10.037. Epub 2017 Oct 27. PMID:29103972 doi:http://dx.doi.org/10.1016/j.bmcl.2017.10.037

5xmx, resolution 2.00Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA